Dr Guillaume Zagury
Chief Executive Officer
Medical background with business training from HEC Paris and experience in public health, management and business administration.
Leadership
Scientific depth. Development focus.
A multidisciplinary team spanning immunology, clinical research, biotechnology strategy and organizational leadership.
Management
Company leadership
Prof. Jean-François Zagury
Chief Scientific Officer
MD, PhD in immuno-virology; Chair of Bioinformatics at CNAM and leader of its genomics, bioinformatics and molecular chemistry laboratory.
Dr Abderrahim Lachgar
Strategy
More than 25 years of biotechnology executive experience, including leadership of immunotherapy-related development programs.
Scientific & medical expertise
Advisory and development leadership
Prof. Armand Bensussan
Chairman, Scientific Advisory Board
Research and laboratory leadership experience at INSERM and Institut du Cancer Jean Godinot.
Dr Hélène Le Buanec
R&D & Advisor
CNRS research background with academic and industrial experience in preclinical and clinical R&D, particularly immunomodulation.
Prof. Alessandro Gringeri
Medical Director
Professor of Hematology in Milan with international hospital, pharmaceutical and HIV/AIDS clinical-trial experience.
The scientific foundation informing Dys-Immune Therapeutics, including the work of Prof. Daniel Zagury, is presented on the Company page.
Scientific heritage